ResearcherUniversitätsmedizin RostockActive in the last 2 years
Brigitte Vollmar
Matched on ORCID iD 0000-0002-2403-9597; OpenAlex author ID A5081747456. Sources: OpenAlex.
Their work
- Papers
- 17 (first author 0, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 18
2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper
Papers 17
- Targeting pancreatic cancer with combined inhibition of EGFR and RAF. Co-author DOI 10.1371/journal.pone.0347843↗
- Burrowing Behavior as Robust Parameter for Early Humane Endpoint Determination in Murine Models for Pancreatic Cancer. Co-author DOI 10.3390/ani15091241↗
- Evidence-Based Severity Assessment of Animal Models for Pancreatic Cancer. Co-author DOI 10.3390/biomedicines12071494↗
- Sex Matters-Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer. Co-author DOI 10.3390/cancers16101901↗
- Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism. Co-author DOI 10.1371/journal.pone.0266601↗
- Voluntary wheel running behaviour as a tool to assess the severity in a mouse pancreatic cancer model. Co-author DOI 10.1371/journal.pone.0261662↗
- Benefits of non-invasive methods compared to telemetry for distress analysis in a murine model of pancreatic cancer. Co-author DOI 10.1016/j.jare.2019.09.002↗
- Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells. Co-author DOI 10.21873/anticanres.13936↗
- Metformin and LW6 impairs pancreatic cancer cells and reduces nuclear localization of YAP1. Co-author DOI 10.7150/jca.33029↗
- LW6 enhances chemosensitivity to gemcitabine and inhibits autophagic flux in pancreatic cancer. Co-author DOI 10.1016/j.jare.2019.04.006↗
- α-cyano-4-hydroxycinnamate impairs pancreatic cancer cells by stimulating the p38 signaling pathway. Co-author DOI 10.1016/j.cellsig.2018.03.015↗
- Blocking Autophagy in Cancer-Associated Fibroblasts Supports Chemotherapy of Pancreatic Cancer Cells. Co-author DOI 10.3389/fonc.2018.00590↗
- Metformin Inhibits Gemcitabine Induced Apoptosis in Pancreatic Cancer Cell Lines. Last author DOI 10.7150/jca.17972↗
- Analysis of Axin2 expression and function in murine models for pancreatic cancer. Last author DOI 10.1186/s13578-016-0116-4↗
- Impact of diabetes type II and chronic inflammation on pancreatic cancer. Last author DOI 10.1186/s12885-015-1047-x↗
- Characterization of novel carcinoma cell lines for the analysis of therapeutical strategies fighting pancreatic cancer. Last author DOI 10.1186/s13578-015-0038-6↗
- Risk factors for pancreatic ductal adenocarcinoma specifically stimulate pancreatic duct glands in mice. Co-author DOI 10.1016/j.ajpath.2012.11.016↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dietmar Zechner · 16 shared papers, 2013–2025 · strength 1.90
- Paper Burrowing Behavior as Robust Parameter for Early Humane Endpoint Determination in Murine Models for Pancreatic Cancer. DOI 10.3390/ani15091241↗
- Paper Sex Matters-Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer. DOI 10.3390/cancers16101901↗
- Paper Evidence-Based Severity Assessment of Animal Models for Pancreatic Cancer. DOI 10.3390/biomedicines12071494↗
- Simone Kumstel · 10 shared papers, 2018–2026 · strength 1.52
- Paper Targeting pancreatic cancer with combined inhibition of EGFR and RAF. DOI 10.1371/journal.pone.0347843↗
- Paper Burrowing Behavior as Robust Parameter for Early Humane Endpoint Determination in Murine Models for Pancreatic Cancer. DOI 10.3390/ani15091241↗
- Paper Evidence-Based Severity Assessment of Animal Models for Pancreatic Cancer. DOI 10.3390/biomedicines12071494↗
- Tim Schreiber · 5 shared papers, 2022–2026 · strength 1.08
- Paper Targeting pancreatic cancer with combined inhibition of EGFR and RAF. DOI 10.1371/journal.pone.0347843↗
- Paper Burrowing Behavior as Robust Parameter for Early Humane Endpoint Determination in Murine Models for Pancreatic Cancer. DOI 10.3390/ani15091241↗
- Paper Sex Matters-Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer. DOI 10.3390/cancers16101901↗
- Jakob Brandstetter · 3 shared papers, 2024–2026 · strength 0.74
- Paper Targeting pancreatic cancer with combined inhibition of EGFR and RAF. DOI 10.1371/journal.pone.0347843↗
- Paper Burrowing Behavior as Robust Parameter for Early Humane Endpoint Determination in Murine Models for Pancreatic Cancer. DOI 10.3390/ani15091241↗
- Paper Evidence-Based Severity Assessment of Animal Models for Pancreatic Cancer. DOI 10.3390/biomedicines12071494↗
- Xianbin Zhang · 6 shared papers, 2018–2022 · strength 0.66
- Paper Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism. DOI 10.1371/journal.pone.0266601↗
- Paper Benefits of non-invasive methods compared to telemetry for distress analysis in a murine model of pancreatic cancer. DOI 10.1016/j.jare.2019.09.002↗
- Paper Metformin and LW6 impairs pancreatic cancer cells and reduces nuclear localization of YAP1. DOI 10.7150/jca.33029↗
- Maria Schönrogge · 5 shared papers, 2016–2022 · strength 0.55
- Paper Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells. DOI 10.21873/anticanres.13936↗
- Paper Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism. DOI 10.1371/journal.pone.0266601↗
- Paper α-cyano-4-hydroxycinnamate impairs pancreatic cancer cells by stimulating the p38 signaling pathway. DOI 10.1016/j.cellsig.2018.03.015↗
- Edgar Heinz Uwe Wendt · 4 shared papers, 2018–2022 · strength 0.50
- Paper Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells. DOI 10.21873/anticanres.13936↗
- Paper Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism. DOI 10.1371/journal.pone.0266601↗
- Paper Benefits of non-invasive methods compared to telemetry for distress analysis in a murine model of pancreatic cancer. DOI 10.1016/j.jare.2019.09.002↗
- Benjamin Schulz · 2 shared papers, 2024–2025 · strength 0.45
- Robert Jaster · 2 shared papers, 2018–2024 · strength 0.26
- Florian Bürtin · 3 shared papers, 2015–2017 · strength 0.21
- Paper Metformin Inhibits Gemcitabine Induced Apoptosis in Pancreatic Cancer Cell Lines. DOI 10.7150/jca.17972↗
- Paper Impact of diabetes type II and chronic inflammation on pancreatic cancer. DOI 10.1186/s12885-015-1047-x↗
- Paper Characterization of novel carcinoma cell lines for the analysis of therapeutical strategies fighting pancreatic cancer. DOI 10.1186/s13578-015-0038-6↗
- Yixuan Ma · 1 shared paper, 2024 · strength 0.20
- Hugo Murua Escobar · 1 shared paper, 2024 · strength 0.20
- Nora Weegh · 1 shared paper, 2021 · strength 0.12
- Christine Häger · 1 shared paper, 2021 · strength 0.12
- Peng Gong · 1 shared paper, 2020 · strength 0.12
- Peng Gong · 1 shared paper, 2019 · strength 0.11
- Lars Ivo Partecke · 1 shared paper, 2015 · strength 0.06
- Alexej Bobrowski · 1 shared paper, 2013 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.